IP Library › Granted Patent US 12,365,872
Granted Patent B2
US 12,365,872 · App. 17/277,548 · Granted Jul 22, 2025

Methods for differentiating pluripotent stem cells in dynamic suspension culture

Inventors: Rekha R. Nair (Mountain View, CA); Stephanie Kayser (Mountain View, CA); Abhirath S. Parikh (Los Angeles, CA); Uzma Shoukat-Mumtaz (Fremont, CA); Erik Michael Whiteley (Concord, CA); Nathan C. Manley (San Jose, CA); Craig R. Halberstadt (Pleasanton, CA)
Assignee: LINEAGE CELL THERAPEUTICS, INC.
C12N5/0622C12N5/0068C12N2500/46C12N2501/11C12N2501/115C12N2501/135C12N2501/15C12N2501/155C12N2501/16C12N2501/385C12N2501/41C12N2506/02C12N2506/03C12N2506/45C12N2533/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,365,872
App. No.
17/277,548
Granted
Jul 22, 2025
Kind
B2
Abstract

Methods for differentiating pluripotent stem cells to neuroectoderm in dynamic suspension culture using small molecule or protein inhibitors of TGFβ/Activin/Nodal signaling and BMP signaling are provided. Also provided are methot and protocols for differentiating pluripotent stem cells such as human embryonic stem cells first to neuroectoderm, then further to glial progenitor cells, and further to oligodendrocyte progenitor cells (OPCs), and compositions obtained thereby. The methods of the present disclosure reproducibly produce neuroectoderm progenitor cells by day 7 of the differentiation process, glial progenitor cells by day 21 of the differentiation process and OPCs by day 42 of the differentiation process.

Claims (29)

1. A method for obtaining a population of cells comprising glial progenitor cells from undifferentiated human pluripotent stem cells, the method comprising:

a) obtaining a suspension culture of non-embryoid body (non-EB) aggregates of undifferentiated human pluripotent stem cells, wherein the human pluripotent stem cells remain in an undifferentiated state;

b) culturing the non-EB aggregates from a) in dynamic suspension in the presence of at least one inhibitor of transforming growth factor beta (TGFβ)/Activin/Nodal signaling selected from an inhibitor of activin receptor-like kinase 5 (ALK5), SB431542, LY2157299, GW788388, A-77-01, A-83-01 or SB505124 and at least one inhibitor of bone morphogenetic protein (BMP) signaling selected from an activin receptor-like kinase 2 (ALK2), Dorsomorphin, DMH-1, K02288, ML3467, LDN193189 or Noggin protein for a first time period, thereby inducing differentiation to neuroectoderm lineage cells, wherein the first time period is three to four days;

c) culturing the neuroectoderm lineage cells from b) in dynamic suspension in the presence of retinoic acid and at least one agonist of Smoothened receptor for a second time period, wherein the second time period is three to four days; and

d) culturing the neuroectoderm lineage cells from c) in dynamic suspension in the presence of basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) for a further time period, until the cells have matured into glial progenitor cells, wherein steps a) through d) are performed over a period of about 21 days, wherein about refers to a variation of ±10%.

2. The method of claim 1 , further comprising an additional step of harvesting the glial progenitor cells from d) and plating them onto a substrate.

3. The method of claim 2 , wherein the substrate is recombinant human laminin-521.

4. The method of claim 1 , wherein the human pluripotent stem cells are human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs).

5. The method of claim 1 , wherein the at least one Smoothened receptor agonist is selected from the group consisting of Purmorphamine, Smoothened Agonist and Sonic Hedgehog (SHH) protein.

6. A method for obtaining a population of cells comprising oligodendrocyte progenitor cells (OPCs) from undifferentiated human pluripotent stem cells, the method comprising:

a) obtaining glial progenitor cells according to the method of claim 1 ;

b) harvesting the cells from a) and plating them onto a substrate; and

c) culturing the cells from b) in the presence of epidermal growth factor (EGF) and platelet-derived growth factor AA (PDGF-AA) for a further time period, until the cells have matured into OPCs, wherein the OPCs express one or more markers selected from neural/glial antigen 2 (NG2), platelet-derived growth factor receptor A (PDGFRα), and ganglioside GD3 (GD3).

7. The method of claim 6 , wherein the culturing of step c performed for a period of about 21 days.

8. The method of claim 6 , wherein the substrate is selected from: (i) a cell adhesion peptide and (ii) an extracellular matrix selected from laminin and vitronectin.

9. The method of claim 6 , wherein the substrate is recombinant human laminin-521 or laminin-511 E8 fragment.

10. The method of claim 6 , wherein the human pluripotent stem cells are hESCs or hiPSCs.

11. A method for inducing differentiation of human pluripotent stem cells into paired box 6 (PAX6) positive neuroectoderm cells, the method comprising:

a) obtaining a suspension culture of non-embryoid body (non-EB) aggregates of undifferentiated human pluripotent stem cells, wherein the human pluripotent stem cells remain in an undifferentiated state;

b) culturing the non-EB aggregates from a) in dynamic suspension in the presence of at least one inhibitor of transforming growth factor beta (TGFβ)/Activin/Nodal signaling selected from an inhibitor of activin receptor-like kinase 5 (ALK5), SB431542, LY2157299, GW788388, A-77-01, A-83-01 or SB505124 and at least one inhibitor of bone morphogenetic protein (BMP) signaling selected from an activin receptor-like kinase 2 (ALK2), Dorsomorphin, DMH-1, K02288, ML3467, LDN193189 or Noggin protein for a first time period, thereby inducing differentiation to neuroectoderm lineage cells, wherein the first time period is three to four days;

c) culturing the neuroectoderm lineage cells from b) in dynamic suspension in the presence of retinoic acid and at least one agonist of Smoothened receptor for a second time period, wherein the second time period is three to four days; until the cells have matured into paired box 6 (PAX6) positive neuroectoderm cells.

12. The method of claim 11 , wherein the human pluripotent stem cells are human embryonic stem cells (hESCs) or human induced pluripotent stem cells (hiPSCs).

13. The method of claim 11 , wherein the at least one Smoothened receptor agonist is A selected from the group consisting of Purmorphamine, Smoothened Agonist and Sonic Hedgehog (SHH) protein.

14. The method of claim 11 , wherein steps a) through c) are performed over a period of about 7 to 8 days, wherein about refers to a variation of 10%.

15. A method for obtaining a population of cells comprising glial progenitor cells from undifferentiated human pluripotent stem cells, the method comprising:

a) culturing undifferentiated human pluripotent stem cells that have been disaggregated and form a single-cell suspension in dynamic suspension to obtain non-embryoid body (non-EB) aggregates, wherein the human pluripotent stem cells in the non-EB aggregates remain in an undifferentiated state;

b) culturing the non-EB aggregates from a) in dynamic suspension in the presence of at least one inhibitor of transforming growth factor beta (TGFf3)/Activin/Nodal signaling selected from an inhibitor of activin receptor-like kinase 5 (ALK5), SB431542, LY2157299, GW788388, A-77-01, A-83-01 or SB505124 and at least one inhibitor of bone morphogenetic protein (BMP) signaling selected from an activin receptor-like kinase 2 (ALK2), Dorsomorphin, DMH-1, K02288, ML3467, LDN193189 or Noggin protein for a first time period, thereby inducing differentiation to neuroectoderm lineage cells, wherein the first time time period is three to four days;

c) culturing the neuroectoderm lineage cells from b) in dynamic suspension in the presence of retinoic acid and at least one agonist of Smoothened receptor for a second time period, wherein the second time period is three to four days; and

d) culturing the neuroectoderm lineage cells from c) in dynamic suspension in the presence of basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) for a further time period, until the cells have matured into glial progenitor cells, wherein steps a) through d) are performed over a period of 21 days.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 9, 2022
From: NAIR, REKHA R.; SHOUKAT-MUMTAZ, UZMA; WHITELEY, ERIK MICHAEL; MANLEY, NATHAN C.; HALBERSTADT, CRAIG R.; PARIKH, ABHIRATH S.
To: ASTERIAS BIOTHERAPEUTICS, INC.
Reel/Frame 061052/0302 →
Continuity (2)
Provisional Application 62733621 · Sep 19, 2018
Related Publication 20220267723A1 · Aug 25, 2022
References Cited (190)
US 6280718B1 · Kaufman et al. · 2001 [cited by applicant]
US 7285415B2 · Keirstead et al. · 2007 [cited by applicant]
US 7390659B2 · Jessell et al. · 2008 [cited by applicant]
US 7524489B2 · Messina et al. · 2009 [cited by applicant]
US 7579188B2 · Keirstead et al. · 2009 [cited by applicant]
US 8137969B2 · Reubinoff et al. · 2012 [cited by applicant]
US 8227247B2 · Zhang et al. · 2012 [cited by applicant]
US 8911777B2 · Coulter · 2014 [cited by applicant]
US 9238794B2 · Shogbon et al. · 2016 [cited by applicant]
US 9862925B2 · Aharonowiz et al. · 2018 [cited by applicant]
US 9969974B2 · Tesar · 2018 [cited by examiner]
US 10138292B2 · Tryggvason et al. · 2018 [cited by applicant]
US 10286009B2 · Wirth, III et al. · 2019 [cited by applicant]
US 10301592B2 · Fossati et al. · 2019 [cited by applicant]
US 10450546B2 · Goldman et al. · 2019 [cited by applicant]
US 10676716B2 · Fossati et al. · 2020 [cited by applicant]
US 20040009593A1 · Keirstead et al. · 2004 [cited by applicant]
US 20100015702A1 · Rao et al. · 2010 [cited by applicant]
US 20100158878A1 · Capela et al. · 2010 [cited by applicant]
US 20100159595A1 · Zhang et al. · 2010 [cited by applicant]
US 20100166720A1 · Vanderhaeghen et al. · 2010 [cited by applicant]
US 20100239541A1 · Johe et al. · 2010 [cited by applicant]
US 20110059055A1 · Goldman et al. · 2011 [cited by applicant]
US 20120100113A1 · Tesar et al. · 2012 [cited by applicant]
US 20120177614A1 · Kido · 2012 [cited by applicant]
US 20130004467A1 · Goldman et al. · 2013 [cited by applicant]
US 20130143805A1 · Whittaker et al. · 2013 [cited by applicant]
US 20130210109A1 · Lebkowski et al. · 2013 [cited by applicant]
US 20130280219A1 · Shiels · 2013 [cited by applicant]
US 20140170634A1 · Woods · 2014 [cited by applicant]
US 20140186955A1 · Vanderhaeghen et al. · 2014 [cited by applicant]
US 20140248696A1 · Zhang et al. · 2014 [cited by applicant]
US 20150017139A1 · Huang et al. · 2015 [cited by applicant]
US 20150050667A1 · Carson et al. · 2015 [cited by applicant]
US 20150224331A1 · Marsala · 2015 [cited by applicant]
US 20160015707A1 · Tesar et al. · 2016 [cited by applicant]
US 20160030490A1 · Lanza et al. · 2016 [cited by applicant]
US 20160075994A1 · Tesar et al. · 2016 [cited by applicant]
US 20160152950A1 · Zhang et al. · 2016 [cited by applicant]
US 20160331786A1 · Wirth et al. · 2016 [cited by applicant]
US 20180237748A9 · Chambers et al. · 2018 [cited by applicant]
US 20190262405A1 · Wirth et al. · 2019 [cited by applicant]
US 20190336538A1 · Wirth et al. · 2019 [cited by applicant]
US 20200231932A1 · Onishi et al. · 2020 [cited by applicant]
US 20210189335A1 · Whiteley et al. · 2021 [cited by applicant]
US 20230139899A1 · Onishi et al. · 2023 [cited by applicant]
CN 1833021A · 2006 [cited by applicant]
CN 1852971A · 2006 [cited by applicant]
CN 102160546A · 2011 [cited by applicant]
CN 102803472A · 2012 [cited by applicant]
CN 105624116A · 2016 [cited by applicant]
CN 107109367A · 2017 [cited by applicant]
JP 2003533224A · 2003 [cited by applicant]
JP 2006517084A · 2006 [cited by applicant]
JP 2010536357A · 2010 [cited by applicant]
JP 2011514147A · 2011 [cited by applicant]
JP 2017511153A · 2017 [cited by applicant]
JP 2022501049A · 2022 [cited by applicant]
KR 20090035372A · 2009 [cited by applicant]
WO 9848001A1 · 1998 [cited by applicant]
WO 0128342A1 · 2001 [cited by applicant]
WO 0188104A2 · 2001 [cited by applicant]
WO 2004007665A2 · 2004 [cited by applicant]
WO 2005007797A2 · 2005 [cited by applicant]
WO 2009097421A1 · 2009 [cited by applicant]
WO 2010151782A1 · 2010 [cited by applicant]
WO 2012096705A1 · 2012 [cited by applicant]
WO 2014047540A1 · 2014 [cited by applicant]
WO 2014124087A1 · 2014 [cited by applicant]
WO 2015143342A1 · 2015 [cited by applicant]
WO 2015179822A1 · 2015 [cited by applicant]
WO 2016103269A1 · 2016 [cited by applicant]
WO 2017132596A1 · 2017 [cited by applicant]
WO WO2017173064A1 · 2017 [cited by examiner]
WO 2018053210A1 · 2018 [cited by applicant]
WO 2020061371A2 · 2020 [cited by applicant]
Li et al. Targeting the TGF-β signaling pathway for fibrosis therapy: a patent review (2015-2020). Expert Opinion of Therapeutic Patents 31: 723-743. (Year: 2021). [cited by examiner]
Gomez-Puerto et al. Bone morphogenetic protein receptor signal transduction in human disease. J Pathol 247: 9-20. (Year: 2019). [cited by examiner]
Bergles et al. Oligodendrocyte Development and Plasticity. Cold Spring Harb Perspect Biol 8: 1-27. (Year: 2016). [cited by examiner]
Zhang et al. An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex . The Journal of Neuroscience 34: 11929-11947. (Year: 2014). [cited by examiner]
Sharifi et al. FABP7 expression in normal and stab-injured brain cortex and its role in astrocyte proliferation. Histochem Cell Biol 136: 501-513. (Year: 2011). [cited by examiner]
Zhang et al. Pax6 Is a Human Neuroectoderm Cell Fate Determinant. Cell Stem Cell 7: 90-100. (Year: 2010). [cited by examiner]
Eze Supplemental Information. Single-cell atlas of early human brain development highlights heterogeneity of human neuroepithelial cells and early radial glia Nature Neuroscience 24. 584-594. (Year: 2021). [cited by examiner]
Tailor et al. Stem Cells Expanded from the Human Embryonic Hindbrain Stably Retain Regional Specification and High Neurogenic Potency. The Journal of Neuroscience 33: 12407-12422. (Year: 2013). [cited by examiner]
Bian et al. Sequential Differentiation of Embryonic Stem Cells into Neural Epithelial-Like Stem Cells and Oligodendrocyte Progenitor Cells. PLoS One 11: 1-15. (Year: 2016). [cited by examiner]
Abecasis et al. Expansion of 3D human induced pluripotent stem cell aggregates in bioreactors: Bioprocess intensification and scaling-up approaches. Journal of Biotechnology 246: 81-93. (Year: 2017). [cited by examiner]
Eze et al. Single-cell atlas of early human brain development highlights heterogeneity of human neuroepithelial cells and early radial glia Nature Neuroscience 24. 584-594. (Year: 2021). [cited by examiner]
Medina-Rodriguez et al. Protocol to Isolate a Large Amount of Functional Oligodendrocyte Precursor Cells from the Cerebral Cortex of Adult Mice and Humans. PLoS One 8: 1-13. (Year: 2013). [cited by examiner]
Xue et al. Proliferation, multipotency and neuronal differentiation of cryopreserved neural progenitor cells derived from the olfactory neuroepithelium of the adult rat. Cell Biology International 32: 950-958. (Year: 20… [cited by examiner]
Yu et al. ERK inhibition promotes neuroectodermal precursor commitment by blocking self-renewal and primitive streak formation of the epiblast. Stem Cell Research & Therapy 9: 1-13. (Year: 2018). [cited by examiner]
Abiraman et al. Anti-Muscarinic Adjunct Therapy Accelerates Functional Human Oligodendrocyte Repair. The Journal of Neuroscience 35:3676-3688. (Year: 2015). [cited by examiner]
Xue et al. Mechanics-guided embryonic patterning of neuroectoderm tissue from human pluripotent stem cells. Nature Materials 17: 633-641. 2018; published Jul. 2018 (Year: 2018). [cited by examiner]
Liu et al. Microfibrous carriers for integrated expansion and neural differentiation of embryonic stem cells in suspension bioreactor. Biochemical Engineering Journal 75: 55-63. (Year: 2013). [cited by examiner]
Nothias et al. (2005) “Combined Effects of Neurotrophin Secreting Transplants, Exercise, and Serotonergic Drug Challenge Improve Function In Spinal Rats”, Neurorehabilitation and Neural Repair, 19(4):296-312. [cited by applicant]
Orentas et al. (Jun. 1999) “Sonic Hedgehog Signaling is Required During the Appearance of Spinal Cord Oligodendrocyte Precursors”, Development, 126(11):2419-2429. [cited by applicant]
Roy et al. (Oct. 22, 2006) “Functional Engraftment of Human ES Cell-Derived Dopaminergic Neurons Enriched by Coculture with Telomerase-Immortalized Midbrain Astrocytes”, Nature Medicine, 12(11):1259-1268. [cited by applicant]
Scheff et al. (2003) “Experimental Modeling of Spinal Cord Injury: Characterization of a Force-Defined Injury Device”, Journal of Neurotrauma, 20(2):179-193. [cited by applicant]
Sharp et al. (Jan. 2010) “Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cell Transplants Improve Recovery after Cervical Spinal Cord Injury”, Stem Cells, 28(1):152-163. [cited by applicant]
Singh, Juhi (2018) “Role of PDGF-A Activated Intracellular Signalling in Oligodendrocyte Progenitor Migration”, PhD Thesis, 153 pages. [cited by applicant]
Sokol, Sergei Y. (Oct. 2011) “Maintaining Embryonic Stem Cell Pluripotency with WNT Signaling”, 138 (20):4341-4350. [cited by applicant]
Sundberg et al. (2010) “Production and Isolation of NG2+ Oligodendrocyte Precursors from Human Embryonic Stem Cells in Defined Serum-Free Medium”, Stem Cell Research, 5(2):91-103. [cited by applicant]
Tang et al. (2014) “Redirection of Doublecortin-Positive Cell Migration by OverExpression of the Chemokines MCP-1, MIP-1 a and Gro-a in the Adult Rat Brain”, Neuroscience, 260:240-248. [cited by applicant]
Totiou et al. (2005) “Spinal Cord Injury Is Accompanied by Chronic Progressive Demyelination”, The Journal of Comparative Neurology, 486:373-383. [cited by applicant]
Vadivelu et al. (2015) “Ng2+ Progenitors Derived from Embryonic Stem Cells Penetrate Glial Scar and Promote Axonal Outgrowth Into White Matter After Spinal Cord Injury”, Stem Cells Translational Medicine, 4(4):401-411. [cited by applicant]
Wang et al. (2014) “ApoE Mimetic Ameliorates Motor Deficit and Tissue Damage in Rat Spinal Cord Injury”, Journal of Neuroscience Research, 92(7):884-892. [cited by applicant]
Wirth, E. (May 16, 2014) “Phase I Clinical Trial of Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitors In Subjects with Neurologically Complete Thoracic Spinal Cord Injury: Results and Next Steps”, American S… [cited by applicant]
Wright et al. (2014) “Novel Roles for Osteopontin and Clusterin in Peripheral Motor and Sensory Axon Regeneration”, Journal of Neuroscience, 34(5):1689-1700. [cited by applicant]
Zhang et al. (2018) “Highly Efficient Methods to Obtain Homogeneous Dorsal Neural Progenitor Cells From Human and Mouse Embryonic Stem Cells and Induced Pluripotent Stem Cells”, Stem Cell Research and Therapy, 9(67):13 … [cited by applicant]
Zhang et al. (2006) “Oligodendrocyte Progenitor Cells Derived from Human Embryonic Stem Cells Express Neurotrophic Factors”, Stem Cells and Development, 15(6):943-952. [cited by applicant]
Zhang et al. (Apr. 2011) “Role of Matrix Metalloproteinases and Therapeutic Benefits of Their Inhibition in Spinal Cord Injury”, Neurotherapeutics, 8(2):206-220. [cited by applicant]
Hu et al. (Jul. 16, 2009) “Hepatocyte Growth Factor Enhances the Generation of High-purity Oligodendrocytes from Human Embryonic Stem Cells”, Differentiation, 78(2-3):177-184. [cited by applicant]
Hu et al. (Mar. 2, 2010) “Neural Differentiation of Human Induced Pluripotent Stem Cells Follows Developmental Principles but with Variable Potency”, Proc. Natl. Acad. Sci. U.S.A., 107(9):4335-4340. [cited by applicant]
(2018) Enhanced Proliferation of Primary Nscs and Sustained Differentiation Into Precursors Using Heat-stable bFGF, Gibco, 3 pages. [cited by applicant]
European Search Report issued in European Application Application No. 17851575.5, mailed on Mar. 24, 2020, 6 pages. [cited by applicant]
Extended European Search Report for Application No. EP 19862819.0, mailed on Jun. 10, 2022, 11 pages. [cited by applicant]
Extended European search report for EP Application No. 20745781.3, mailed on Oct. 26, 2022, 8 Pages. [cited by applicant]
Extended European Search Report received for European Application No. 17776639.1, mailed on Sep. 26, 2019, 8 pages. [cited by applicant]
(2016) History of Changes for Study: NCT02302157, https://clinicaltrials.gov/ct2/history/NCT02302157?v_17=View#StudyPageTop, 5 pages. [cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2017/051677, Mailed on Mar. 28, 2019, 10 pages. [cited by applicant]
International Preliminary Report on Patentability for PCT Application No. PCT/US2017/24986, mailed on Oct. 11, 2018, 8 pages. [cited by applicant]
International Search Report and Written Opinion for PCT Application No. PCT/US2017/24986, mailed on Aug. 22, 2017, 11 pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US20/014834, mailed on Apr. 23, 2020, 11 Pages. [cited by applicant]
International Search Report and Written Opinion issued in International Application No. PCT/US2017/051677, Mailed on Dec. 4, 2017, 11 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent International Application No. PCT/US2022/014373, mailed on Jun. 30, 2022, 10 pages. [cited by applicant]
International Search Report and Written Opinion received for PCT Patent International Application No. PCT/US22/19847, Mailed on Jun. 27, 2022, 10 pages. [cited by applicant]
Alsanie et al. (2013) “Human Embryonic Stem Cell-Derived Oligodendrocytes: Protocols and Perspectives”, Stem Cells and Development, 22(18):2459-2472. [cited by applicant]
Anderson et al. (Nov. 25, 2008) “Acceptable benefits and risks associated with surgically improving arm function in individuals living with cervical spinal cord injury”, Spinal Cord, 47(4):334-338. [cited by applicant]
Armstrong et al. (Nov. 1990) “Type 1 Astrocytes and Oligodendrocyte-type 2 Astrocyte Glial Progenitors Migrate Toward Distinct Molecules”, Journal of Neuroscience Research, 27(3):400-407. [cited by applicant]
Bain et al. (Apr. 1995) “Embryonic Stem Cells Express Neuronal Properties in Vitro”, Developmental Biology, 168:342-357. [cited by applicant]
Bansod et al. (2017) “Hes5 Regulates the Transition Timing of Neurogenesis and Gliogenesis in Mammalian Neocortical Development”, Development, 3156-3167. [cited by applicant]
Behrmann et al. (1992) “Spinal Cord Injury Produced by Consistent Mechanical Displacement of the Cord in Rats: Behavioral and Histologic Analysis”, Journal of Neurotrauma, 9(3):197-217. [cited by applicant]
Briscoe et al. (Jun. 2001) “A Hedgehog-insensitive Form of Patched Provides Evidence for Direct Long-range Morphogen Activity of Sonic Hedgehog in the Neural Tube”, Molecular Cell, 7(6):1279-1291. [cited by applicant]
Cai et al. (Jan. 6, 2005) “Generation of Oligodendrocyte Precursor Cells from Mouse Dorsal Spinal Cord Independent of Nkx6 Regulation and Shh Signaling”, Neuron, 41-53. [cited by applicant]
Cao et al. (Jan. 2001) “Pluripotent Stem Cells Engrated into the Normal or Lesioned Adult Rat Spinal Cord Are Restricted to a Glial Lineage”, Experimental Neurology, 167(1):48-58. [cited by applicant]
Chapman et al. (Sep. 2012) “Evaluating the First-in-human Clinical Trial of a Human Embryonic Stem Cell-based Therapy”, Kennedy Institute of Ethics Journal, 22(3):243-261. [cited by applicant]
Davies et al. (Mar. 2, 2011) “Transplantation of Specific Human Astrocytes Promotes Functional Recovery after Spinal Cord Injury”, Plos One, e17328, 6(3):13 pages. [cited by applicant]
Doi et al. (Feb. 10, 2012) “Prolonged Maturation Culture Favors a Reduction in the Tumorigenicity and the Dopaminergic Function of Human ESC-Derived Neural Cells in a Primate Model of Parkinson's Disease”, Stem Cells, 3… [cited by applicant]
Douvaras et al. (Aug. 12, 2014) “Efficient Generation of Myelinating Oligodendrocytes from Primary Progressive Multiple Sclerosis Patients by Induced Pluripotent Stem Cells”, Stem Cell Reports, 3(2):250-259. [cited by applicant]
Douvaras et al. (Jul. 2, 2015) “Generation and Isolation of Oligodendrocyte Progenitor Cells From Human Pluripotent Stem Cells”, Nature Protocols, 10:143-1154. [cited by applicant]
Du et al. (2014) “Mechanism of SB431542 in Inhibiting Mouse Embryonic Stem Cell Differentiation”, Cellular Signalling, 26(10):2107-2116. [cited by applicant]
Ericson et al. (Nov. 15, 1996) “Two Critical Periods of Sonic Hedgehog Signaling Required for the Specification of Motor Neuron Identity”, Cell, 87(4):661-673. [cited by applicant]
Faulkner et al. (Dec. 2005) “Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitors for the Treatment of Spinal Cord Injury”, Transplant Immunology, 15(2):131-142. [cited by applicant]
Fuhrmann et al. (Jan. 1, 2016) “Injectable Hydrogel Promotes Early Survival of Induced Pluripotent Stem Cell-Derived Oligodendrocytes and Attenuates Longterm Teratoma Formation in a Spinal Cord Injury Model”, Biomateria… [cited by applicant]
Goldman, Steven A. (Jul. 2005) “Stem and Progenitor Cell-based Therapy of the Human Central Nervous System”, Nature Biotechnology, 23(7):862-871. [cited by applicant]
Gordon et al. (Jan. 2012) “Hemokines Influence The Migration And Fate Of Neural Precursor Cells From The Young Adult And Middle-aged Rat Subventricular Zone”, Experimental Neurology, 233(1):587-594. [cited by applicant]
Hatch et al. (2009) “Derivation of High-Purity Oligodendroglial Progenitors”, Methods in Molecular Biology, 549:59-75. [cited by applicant]
Hu et al. (Oct. 15, 2009) “Differentiation of Human Oligodendrocytes from Pluripotent Stem Cells”, Nature Protocols, 4(11):1614-1622. [cited by applicant]
Hulsebosch et al. (Jan. 29, 2009) “Rodent Model of Chronic Central Pain After Spinal Cord Contusion Injury and Effects of Gabapentin”, Journal of Neurotrauma, 17(12):1205-1217. [cited by applicant]
Karimi-Abdolrezaee et al. (Mar. 29, 2006) “Delayed Transplantation of Adult Neural Precursor Cells Promotes Remyelination and Functional Neurological Recovery After Spinal Cord Injury”, Journal of Neuroscience, 26 (13):… [cited by applicant]
Klimaschewski et al. (Nov. 2001) “Regulation of clusterin expression following spinal cord injury”, Cell and Tissue Research, 306(2):209-216. [cited by applicant]
Kriks et al. (Nov. 6, 2011) “Dopamine Neurons Derived from Human ES Cells Efficiently Engraft In Animal Models of Parkinson's Disease”, Nature, 480(7378):547-551. [cited by applicant]
Kuespert et al. (May 1, 2016) “Something 2 Talk About—Transcriptional Regulation In Embryonic And Adult Oligodendrocyte Precursors”, Brain Research, 1638:16 pages. [cited by applicant]
Kurek et al. (Jan. 13, 2015) “Endogenous WNT Signals Mediate BMP-Induced and Spontaneous Differentiation of Epiblast Stem Cells and Human Embryonic Stem Cells”, Stem Cell Reports, 4(1):114-28. [cited by applicant]
Li et al. (May 15, 2013) “Differentiation Of Oligodendrocyte Progenitor Cells From Human Embryonic Stem Cells On Vitronectin-Derived Synthetic Peptide Acrylate Surface”, Stem Cells and Development, 22(10):1497-1505. [cited by applicant]
Lu et al. (2014) “Long-Distance Axonal Growth from Human Induced Pluripotent Stem Cells After Spinal Cord Injury”, Neuron, 83(4):789-796. [cited by applicant]
Ma et al. (2009) “Oligodendrocyte Precursor Cells Differentially Expressing Noga-A but Not Mag Are More Permissive to Neurite Outgrowth Than Mature Oligodendrocytes”, Experimental Neurology, 217(1):184-196. [cited by applicant]
Metz et al. (2000) “Validation of the Weight-Drop Contusion Model in Rats: A Comparative Study of Human Spinal Cord Injury”, Journal of Neurotrauma, 17(1):1-17. [cited by applicant]
Mitsui et al. (2005) “Transplantation of Neuronal and Glial Restricted Precursors Into Contused Spinal Cord Improves Bladder and Motor Functions, Decreases Thermal Hypersensitivity, and Modifies Intraspinal Circuitry”, … [cited by applicant]
Nakamura et al. (Jun. 20, 2005) “Transplantation of Embryonic Spinal Cord-Derived Neurospheres Support Growth of Supraspinal Projections and Functional Recovery After Spinal Cord Injury in the Neonatal Rat”, Journal of … [cited by applicant]
Nemati et al. (2016) “Scalable Expansion of Human Pluripotent Stem Cell-Derived Neural Progenitors in Stirred Suspension Bioreactor Under Xeno-free Condition”, Methods in Molecular Biology, 1502:143-58. [cited by applicant]
Nistor et al. (Feb. 2005) “Human Embryonic Stem Cells Differentiate into Oligodendrocytes in High Purity and Myelinate After Spinal Cord Transplantation”, Glia, 49(3):385-396. [cited by applicant]
Noble et al. (2011) “Precursor Cell Biology and the Development of Astrocyte Transplantation Therapies: Lessons from Spinal Cord Injury”, Neurotherapeutics, 8(4):677-693. [cited by applicant]
Chew et al. (2014) “Finding Degrees of Separation: Experimental Approaches for Astroglial and Oligodendroglial Cell Isolation and Genetic Targeting”, Journal of Neuroscience Methods, 236:125-147 (23 pages). [cited by applicant]
Clausi et al. (2017) “Delayed ALK5 Inhibition Improves Functional Recovery in Neonatal Brain Injury”, Journal of Cerebral Blood Flow and Metabolism, 37(3):787-800. [cited by applicant]
Kim et al. (2010) “Robust Enhancement of Neural Differentiation From Human ES and iPS Cells Regardless of Their Innate Difference in Differentiation Propensity”, Stem cell reviews and reports, 6(2):270-281. [cited by applicant]
Lukovic et al. (2017) “Highly Efficient Neural Conversion of Human Pluripotent Stem Cells in Adherent and Animal-Free Conditions”, Stem Cells Translational Medicine, 6(4):1217-1226. [cited by applicant]
Najm et al. (2011) “Rapid and Robust Generation of Functional Oligodendrocyte Progenitor Cells From Epiblast Stem Cells”, Nature Methods, 8(11):957-962. [cited by applicant]
Ebrahimi-Barough et al. (Oct. 2013) “Differentiation of Human Endometrial Stromal Cells into Oligodendrocyte Progenitor Cells (OPCs)”, Journal of Molecular Neuroscience, 51(2):265-273. [cited by applicant]
Gallo et al. (1995) “Developmental and Growth Factor-induced Regulation of Nestin in Oligodendrocyte Lineage Cells”, Journal of Molecular Neuroscience, 15(1):394-406. [cited by applicant]
Shin et al. (Sep. 17, 2021) “Sensitive Timing of Undifferentiation in Oligodendrocyte Progenitor Cells and Their Enhanced Maturation in Primary Visual Cortex of Binocularly Enucleated Mice”, PLoS One, 16(9):e0257395 (26… [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2023/061506, mailed on Jul. 3, 2023, 13 pages. [cited by applicant]
Abbasalizadeh et al. (2012) “Bioprocess Development For Mass Production of Size-Controlled Human Pluripotent Stem Cell Aggregates in Stirred Suspension Bioreactor”, Tissue Engineering: Part C Methods, 18(11):831-851. [cited by applicant]
Bardy et al. (Feb. 1, 2013) “Microcarrier Suspension Cultures for High-Density Expansion and Differentiation of Human Pluripotent Stem Cells to Neural Progenitor Cells”. Tissue Engineering. Part C, Methods, 19(2):166-18… [cited by applicant]
Hu et al. (May 2009) “Human Oligodendrocytes From Embryonic Stem Cells: Conserved SHH Signaling Networks and Divergent FGF Effects”, Development, 136(9):1443-1452. [cited by applicant]
Kimura et al. (2012) “Ultrasonographic Quantification of Spinal Cord and Dural Pulsations during Cervical Laminoplasty in Patients with Compressive Myelopathy”, Eur, Spine J., 21(12):2450-2455. [cited by applicant]
Manley et al. (Oct. 2017) “Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cells: Preclinical Efficacy and Safety in Cervical Spinal Cord Injury”, Stem Cells Translational Medicine, 6(10):1917-1929. [cited by applicant]
Munst et al. (2018) “In Vitro Segregation and Isolation of Human Pluripotent Stem Cell-Derived Neural Crest Cells”, Methods, 133:65-80 (49 pages). [cited by applicant]
Ota et al. (Mar. 2006) “BMP and FGF-2 Regulate Neurogenin-2 Expression and the Differentiation of Sensory Neurons and Glia”, Developmental Dynamics, 235(3):646-655. [cited by applicant]
Patthey et al. (Feb. 1, 2014) “Signaling Pathways Regulating Ectodermal Cell Fate Choices”, Experimental Cell Research, 321(1):11-16. [cited by applicant]
Riemens et al. (Sep. 2018) “Directing Neuronal Cell Fate in Vitro: Achievements and Challenges”, Progress in Neurobiology, 168:42-68 (130 pages). [cited by applicant]
Vigil et al. (Apr. 2008) “Efficacy of Tacrolimus In Inhibiting Inflammation Caused by Carrageenan in a Murine Model of Air Pouch”, Transplant Immunology, 19(1):25-29. [cited by applicant]
Zheng et al. (Aug. 2018) Differentiation of Glial Cells From hiPSCs: Potential Applications in Neurological Diseases and Cell Replacement Therapy, Frontiers in Cellular Neuroscience, 12:239 (21 pages). [cited by applicant]
Fischer et al. (Jul. 2020) “Transplanting Neural Progenitor Cells To Restore Connectivity After Spinal Cord Injury”, Nature Reviews Neuroscience, 21(7):366-383. [cited by applicant]
Zhou et al. (Apr. 2, 2014) “GSK3β Promotes the Differentiation of Oligodendrocyte Precursor Cells via β-Catenin-Mediated Transcriptional Regulation”, Molecular Neurobiology, 50:507-519. [cited by applicant]
Franz, et al., “Motor Levels in High Cervical Spinal cord injuries: Implications for the International Standards for Neurological Classification of Spinal Cord Injury”, The Journal of Spinal Cord Medicine 39(5), 513-517… [cited by applicant]
Ilic, Dusko, Latest Developments in the Field of Stem Cell Research and Regenerative Medicines Regenerative Medicine', 9(6):713-719., Nov. 28, 2014. [cited by applicant]
Marcantonini, et al., “Natural Cryoprotective and Cytoprotective Agents in Cryopreservation: A Focus on Melatonin Molecules”, 27(10):3254 (pp. 1-17)., May 19, 2022. [cited by applicant]
Milosevic, et al., “Cryopreservation Does Not Affect Proliferation And Multipotency Of Murine Neural Precursor Cells”, Stem Cells, 23(5):681-688., May 2005. [cited by applicant]
Raju, et al., “The Need For Novel Cryoprotectants And Cryopreservation Protocols: Insights Into The Importance Of Biophysical Investigation And Cell Permeability”, Biochimica et Biophysica Acta (BBA)—General Subjects, 1… [cited by applicant]
Stylianou, et al., “Novel Cryoprotectant Significantly Improves the Post-thaw Recovery and Quality of HSC from CB”, Cytotherapy 8(1):57-61., 2006. [cited by applicant]
Cited By (1)
US 12,716,054